Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurosense Therapeutics Ltd. ( (NRSN) ) has shared an announcement.
On March 24, 2026, NeuroSense Therapeutics reported that it has rescheduled a pre-New Drug Submission meeting with Health Canada to May 2026 to incorporate new clinical, biomarker and survival data for its ALS and Alzheimer’s candidate PrimeC. The company is pursuing Canada’s Notice of Compliance with conditions pathway, while highlighting a previously disclosed 65% reduction in risk of death, an expanding biomarker dataset, FDA clearance for the pivotal Phase 3 PARAGON ALS trial and an imminent readout from its Alzheimer’s study, developments that collectively aim to strengthen its regulatory posture and value proposition in neurodegenerative diseases.
The most recent analyst rating on (NRSN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn), which elevates funding and dilution risk. Technical signals are mixed with a weak longer-term trend despite neutral momentum, and valuation is limited by negative earnings and no dividend support.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company developing disease-modifying combination therapies for neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. Its lead candidate, PrimeC, is an oral fixed-dose formulation of ciprofloxacin and celecoxib, designed to target multiple pathological pathways such as neuron degeneration, inflammation, iron accumulation and impaired RNA regulation.
Average Trading Volume: 219,756
Technical Sentiment Signal: Sell
Current Market Cap: $22.01M
Learn more about NRSN stock on TipRanks’ Stock Analysis page.